Halozyme Therapeutics Inc. Common Stock vs Viasat — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Viasat trades at $72.01 (market cap $9.29B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Viasat for 7 Days on average.
| HALO | VSAT | |
|---|---|---|
Market Cap | $12.58B | $9.29B |
Volume | 2,179,278 | 2,084,105 |
Sector | Health | Technology |
52-Week High | $115.22 | $89.81 |
52-Week Low | $61.63 | $30.35 |
Typical Hold Time | 1 Days | 7 Days |
Enterprise Value | $14.49B | $14.48B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →